Hugel, Inc.
Research Hugel, Inc. (145020.KQ) on Bullrun: market cap KRW 1.93T. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker145020.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 1.93T
- Financial periodQ2 2026
- RevenueKRW 137.90B
- Net incomeKRW 43.34B
- Free cash flowKRW 23.07B
- Gross margin76.7%
Valuation Snapshot
latest market cap is KRW 1.93T.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 1.93T | n/a | n/a | n/a |
Dividend history
About Hugel, Inc.
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Hugel, Inc.'s market cap?
Hugel, Inc.'s market capitalization is KRW 1.93T.
What does Hugel, Inc. do?
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles.